8-K: Microbot Medical Secures Key China Patent, Bolsters IP Portfolio Ahead of LIBERTY System's U.S. Launch

Microbot Medical Inc. announced the grant of a critical patent in China for its LIBERTY Endovascular Robotic System, further strengthening its global intellectual property portfolio and supporting its long-term commercial strategy ahead of an anticipated Q3 2025 U.S. commercial launch.

Summary

• Microbot Medical Inc. issued an aggregate of 1,480,504 shares of its common stock since May 13, 2025, upon the exercise of 221,062 Series E and 1,259,442 Series F preferred investment options.
• The exercise price for these options was $1.50 per share, generating gross proceeds of approximately $2.22 million to the Company before deducting fees and expenses.
• The shares were issued pursuant to the exemption provided in Section 4(a)(2) under the Securities Act of 1933, as amended, as transactions not involving any public offering.
• The Company was granted a patent in China by the China National Intellectual Property Administration (CNIPA), covering the robotic manipulation of a surgical tool handle.
• This new patent increases the total global patents for the LIBERTY Endovascular Robotic System to nine, with 59 patent applications currently pending.
• Microbot Medical's primary objective remains focused on the U.S. market and preparing for the anticipated Q3 2025 commercial launch of the LIBERTY Endovascular Robotic System, upon planned FDA clearance.
• Preparations for the anticipated U.S. launch are accelerating, encompassing regulatory, operational, and commercial activities.
• The Company is also laying the groundwork to enter international markets to maximize the long-term potential of the LIBERTY system.
• The estimated market opportunity includes over two million peripheral endovascular procedures performed annually in the U.S. and approximately 2.9 million in China.

Sentiment

Score: 7

Explanation: The document highlights positive developments in intellectual property expansion and capital generation from option exercises, alongside progress towards a key commercial launch. However, it also explicitly lists significant risks inherent to a pre-commercial stage medical technology company, including the need for additional capital and regulatory uncertainties.

Positives

• Successful exercise of 1,480,504 preferred investment options, generating approximately $2.22 million in gross proceeds, providing capital for operations.
• Granting of a key patent in China by the China National Intellectual Property Administration (CNIPA), significantly expanding the company's global intellectual property portfolio.
• The new patent covers the robotic manipulation of a surgical tool handle, further validating the Company's technological innovation.
• The LIBERTY Endovascular Robotic System's IP portfolio now includes nine patents granted globally and 59 patent applications pending, enhancing competitive advantage.
• Accelerating regulatory, operational, and commercial activities indicate strong progress towards the anticipated Q3 2025 U.S. commercial launch of the LIBERTY System.
• Strategic groundwork is being laid for entry into international markets, aiming to maximize the long-term global potential of the LIBERTY system.
• Identification of a significant market opportunity with over two million peripheral endovascular procedures annually in the U.S. and 2.9 million in China.

Risks

• The Company's need for and ability to obtain additional working capital to continue its transition to a commercially focused company.
• General market conditions that may impact the Company's operations or financial performance.
• Risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic System.
• Uncertainty in the results of regulatory pathways and regulatory approvals, specifically whether the FDA will timely grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic System in the United States, if at all.
• Uncertainty resulting from political, social, and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S.
• Potential disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran, and other neighboring countries.
• Challenges related to the maintenance and enforcement of intellectual property rights globally.

Future Outlook

Microbot Medical is focused on the anticipated Q3 2025 U.S. commercial launch of its LIBERTY Endovascular Robotic System, pending FDA clearance, with accelerating regulatory, operational, and commercial activities. Concurrently, the company is preparing to enter international markets to maximize the system's long-term potential, targeting significant opportunities in both developed and emerging markets like China.

Management Comments

• "As we move closer to our projected U.S. commercial launch of the LIBERTY System, upon planned FDA clearance, we continue to take the necessary steps to build and protect the foundation for sustained growth and global reach." Harel Gadot, Chairman, CEO & President.
• "With an estimated over two million peripheral endovascular procedures performed annually in the U.S., and another approximately 2.9 million estimated in China, we believe the opportunity to impact developed and emerging markets is significant." Harel Gadot, Chairman, CEO & President.
• "Expanding access to endovascular robotics is central to our mission to improve patient outcomes and enhance procedural capabilities for physicians worldwide."

Industry Context

This announcement positions Microbot Medical as a growing player in the endovascular robotics market, emphasizing intellectual property protection and global expansion. The focus on the LIBERTY system, designed to be single-use and fully disposable, aims to address traditional barriers to advanced robotic systems, potentially disrupting the market by offering a more accessible solution. The company is targeting a significant market with millions of peripheral endovascular procedures annually in the U.S. and China, indicating a strong belief in the market demand for innovative robotic solutions.

Stakeholder Impact

• Shareholders: Potential for increased value due to IP expansion, capital infusion, and progress towards commercialization. Dilution from option exercises is already factored into the share count.
• Patients: Potential for improved outcomes and enhanced procedural capabilities through expanded access to endovascular robotics.
• Physicians: Enhanced procedural capabilities and access to advanced robotic systems.

Next Steps

• Continue preparations for the anticipated Q3 2025 U.S. commercial launch of the LIBERTY Endovascular Robotic System, upon planned FDA clearance.
• Accelerate regulatory, operational, and commercial activities for the U.S. launch.
• Lay groundwork to enter international markets.
• Seek FDA 510(k) clearance for the LIBERTY Endovascular Robotic System.

Key Dates

Keywords

Microbot Medical, LIBERTY Endovascular Robotic System, medical technology, robotics, endovascular, patent, China National Intellectual Property Administration, CNIPA, FDA clearance, commercial launch, intellectual property, medical devices, surgical robotics, healthcare technology